Toxina botulínica en manejo de síntomas del tracto urinario bajo en pacientes con hiperplasia prostática benigna - revisión sistemática de la literatura

dc.contributorEspinosa-Aranzeles, Angela-Fernanda
dc.creatorSánchez Moreno, David
dc.creatorVargas Ovalle, José
dc.date.accessioned2016-03-07T21:43:40Z
dc.date.available2016-03-07T21:43:40Z
dc.date.created2016-03-07T21:43:40Z
dc.date.issued2015
dc.identifierhttp://repository.urosario.edu.co/handle/10336/11813
dc.identifierhttps://doi.org/10.48713/10336_11813
dc.description.abstractSystematic Review of Randomized Clinical Trials Taking literature on the use of the intraprostatic injection of botulinum toxin in patients with benign prostatic hyperplasia evaluating a validated scale of lower urinary tract symptoms as primary outcome
dc.languagespa
dc.publisherUniversidad del Rosario
dc.publisherFacultad de medicina
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto completo)
dc.rightsEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.
dc.sourceMcvary KT. REPORTS BPH : Epidemiology and Comorbidities. 2006;(April):122–8.
dc.sourceBruskewitz RC, Foster HE, Mcnally T, Chan B, Zuckerman M. American Urological Association Guideline : Management of Benign Prostatic Hyperplasia ( BPH ). 2010;
dc.sourceGravas S, Bachmann A, Descazeaud A, Drake M, Gratzke C, Madersbacher S, et al. Guidelines on the Management of Male Lower Urinary Tract Symptoms Benign Prostatic Obstruction ( BPO ). 2014;
dc.sourceRoehrborn CG. Current Medical Therapies for Men With Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: Achievements and Limitations. Rev Urol [Internet]. 2008;10(1):14–25. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2312341/\nhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2312341/pdf/RIU010001_0014.pdf
dc.sourceGarcía-baquero AS, Martínez JS, Reina FB, Chicharro RV, Morales P, Alcaraz DH, et al. Monográfico: ENDOUROLOGÍA Y LÁSER. 2008;9:15–21.
dc.sourceSosnowski R, Borkowski T, Chłosta P, Dobruch J, Fiutowski M, Jaskulski J, et al. Endoscopic simple prostatectomy. Cent Eur J Urol. 2014;67(4):377–84.
dc.sourcede Kort LMO, Kok ET, Jonges TN, Rosier PFWM, Bosch JLHR. Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia. Urology [Internet]. Elsevier; 2012 Oct 10 [cited 2015 Nov 16];80(4):889–93. Available from: http://www.goldjournal.net/article/S0090429512006383/fulltext
dc.sourceChung E. Botulinum toxin in urology: a review of clinical potential in the treatment of urologic and sexual conditions. Expert Opin Biol Ther. 2014/10/28 ed. 2015;15(1):95–102.
dc.sourceCrawford ED, Hirst K, Kusek JW, Donnell RF, Kaplan S a., McVary KT, et al. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: A phase II randomized clinical trial. J Urol [Internet]. Elsevier Inc.; 2011;186(3):965–70. Available from: http://dx.doi.org/10.1016/j.juro.2011.04.062
dc.sourceYokoyama T, Yamamoto Y, Suzuki T, Oguma K, Nagai A. Intraprostatic botulinum neurotoxin type a injection for benign prostatic hyperplasia:preliminary results with a newly purified neurotoxin. Acta Med Okayama [Internet]. 2012;66(4):291–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22918201
dc.sourceSilva J, Pinto R, Carvalho T, Botelho F, Silva P, Oliveira R, et al. Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment. BMC Urol [Internet]. 2009;9:9. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2734751&tool=pmcentrez&rendertype=abstract
dc.sourceChuang Y-C, Chiang P-H, Yoshimura N, De Miguel F, Chancellor MB. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int. 2006;98(5):1033–7; discussion 1337.
dc.sourceKuo H-C, Liu H-T. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. Scand J Urol Nephrol [Internet]. 2009;43(3):206–11. Available from: http://www.tandfonline.com/doi/full/10.1080/00365590902811537
dc.sourceHamidi Madani A, Enshaei A, Heidarzadeh A, Mokhtari G, Farzan A, Mohiti Asli M, et al. Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates. World J Urol [Internet]. 2013;31(1):235–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22411419
dc.sourceMcVary KT, Roehrborn CG, Chartier-Kastler E, Efros M, Bugarin D, Chen R, et al. A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of OnabotulinumtoxinA 200 U to Treat Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia. J Urol [Internet]. Elsevier Ltd; 2014;192(1):150–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24508634
dc.sourceSpeakman MJ, Kirby RS, Joyce a, Abrams P, Pocock R. Guideline for the primary care management of male lower urinary tract symptoms. BJU Int [Internet]. 2004;93(7):985–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15142148
dc.sourceGonzáles Encinales C, Rozo Maragua LE, Castro Muñoz JC, Reyes Calderón JA. Estudio de fármacovigilancia en pacientes con Hiperplasia Prostática Benigna ( HPB ) sintomática tratados con Tamsulosina 0 . 4mg en 8 ciudades de Colombia. Urol Colomb. 2007;(1):107–17.
dc.sourceMaria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: Results of a randomized, placebo-controlled study. Urology. 2003;62(2):259–64.
dc.sourceRoehrborn CG, Nuckolls JG, Wei JT, Steers W. The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics. BJU Int. 2007/09/08 ed. 2007;100(4):813–9.
dc.sourceKumar V, Abbas AK, Aster JC. Patología estructural y funcional. In: Saunders E, editor. 9th ed. Barcelona, España; 2015. p. 982.
dc.sourceWei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2005/03/11 ed. 2005;173(4):1256–61.
dc.sourceKavoussi LR, Partin AW, Novick AC, Peters CA. Urology Campbell - Walsh. In: 10th ed. Philadelphia: Elsevier; 2012. p. 2556–610.
dc.sourceRoehrborn CG. Contemporary Diagnosis and Management of Benign Prostatic Hyperplasia [Internet]. Newtown, Pa: Associates in Medical Marketing Co., Inc; 2009. Available from: http://ez.urosario.edu.co/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=e000xww&AN=382417&lang=es&site=eds-live
dc.sourcePlata Salazar M, Torres Castellanos L. El estudio urodinámico. Urol Colomb [Internet]. 2014;23(2):128–38. Available from: http://www.sciencedirect.com/science/article/pii/S0120789X14500421
dc.sourceRosier PF. The evidence for urodynamic investigation of patients with symptoms of urinary incontinence. F1000Prime Rep [Internet]. 2013;5(March):1–9. Available from: http://www.f1000.com/prime/reports/m/5/8/
dc.sourceNitti VW. Pressure flow urodynamic studies: the gold standard for diagnosing bladder outlet obstruction. Rev Urol. 2005;7 Suppl 6:S14–21.
dc.sourceChancellor MB, Blaivas JG, Kaplan SA, Axelrod S. Bladder outlet obstruction versus impaired detrusor contractility: the role of outflow. J Urol. 1991/04/01 ed. 1991;145(4):810–2.
dc.sourceBarry MJ, Fowler Jr. FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992/11/11 ed. 1992;148(5):1549–57; discussion 1564.
dc.sourceBadia X, Garcia-Losa M, Dal-Re R, Carballido J, Serra M. Validation of a harmonized Spanish version of the IPSS: evidence of equivalence with the original American scale. International Prostate Symptom Score. Urology. 1998/10/08 ed. 1998;52(4):614–20.
dc.sourceJohnson T V, Abbasi A, Ehrlich SS, Kleris RS, Owen-Smith A, Raison CL, et al. IPSS quality of life question: a possible indicator of depression among patients with lower urinary tract symptoms. Can J Urol. 2012/02/10 ed. 2012;19(1):6100–4.
dc.sourceMichel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006/02/09 ed. 2006;147 Suppl :S88–119.
dc.sourceBarendrecht MM, Abrams P, Schumacher H, de la Rosette JJMCH, Michel MC. Do α1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn [Internet]. Wiley Subscription Services, Inc., A Wiley Company; 2008;27(3):226–30. Available from: http://dx.doi.org/10.1002/nau.20481
dc.sourceDjavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2004/12/15 ed. 2004;64(6):1081–8.
dc.sourceRoehrborn CG. Three months’ treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis. 2005/11/24 ed. 2006;9(2):121–5.
dc.sourceRoehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Morrill B, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2007/12/18 ed. 2008;179(2):616–21; discussion 621.
dc.sourceBarendrecht MM, Koopmans RP, de la Rosette JJ, Michel MC. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU Int. 2005/05/06 ed. 2005;95 Suppl 4:19–28.
dc.sourceNaslund MJ, Miner M. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther. 2007/03/24 ed. 2007;29(1):17–25.
dc.sourceNickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ [Internet]. 1996;155(9):1251–9. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1335066&tool=pmcentrez&rendertype=abstract
dc.sourceRoehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2009/10/15 ed. 2010;57(1):123–31.
dc.sourceChess-Williams R, Chapple CR, Yamanishi T, Yasuda K, Sellers DJ. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Aut Pharmacol. 2002/07/19 ed. 2001;21(5-6):243–8.
dc.sourceBraverman AS, Doumanian LR, Ruggieri Sr. MR. M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. II. Denervated rat bladder. J Pharmacol Exp Ther. 2005/10/26 ed. 2006;316(2):875–80.
dc.sourceKedia GT, Uckert S, Jonas U, Kuczyk MA, Burchardt M. The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol. 2008/07/09 ed. 2008;26(6):603–9.
dc.sourceUckert S, Kuthe A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol. 2001/11/07 ed. 2001;166(6):2484–90.
dc.sourceDonatucci CF, Brock GB, Goldfischer ER, Pommerville PJ, Elion-Mboussa A, Kissel JD, et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int. 2011/01/20 ed. 2011;107(7):1110–6.
dc.sourceMadersbacher S, Berger I, Ponholzer A, Marszalek M. Plant extracts: sense or nonsense? Curr Opin Urol. 2007/12/20 ed. 2008;18(1):16–20.
dc.sourceLevin RM, Das AK. A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens. Urol Res. 2000/08/10 ed. 2000;28(3):201–9.
dc.sourceBuck AC. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol. 2004/11/16 ed. 2004;172(5 Pt 1):1792–9.
dc.sourceKaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. Jama. 2006/11/16 ed. 2006;296(19):2319–28.
dc.sourceKuo HC. Prostate botulinum A toxin injection--an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology. 2005/04/19 ed. 2005;65(4):670–4.
dc.sourceChuang YC, Huang CC, Kang HY, Chiang PH, Demiguel F, Yoshimura N, et al. Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol. 2006/02/14 ed. 2006;175(3 Pt 1):1158–63.
dc.sourceSmith CP, Franks ME, McNeil BK, Ghosh R, de Groat WC, Chancellor MB, et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol. 2003/04/11 ed. 2003;169(5):1896–900.
dc.sourceDoggweiler R, Zermann DH, Ishigooka M, Schmidt RA. Botox-induced prostatic involution. Prostate. 1998/08/28 ed. 1998;37(1):44–50.
dc.sourcePark DS, Cho TW, Lee YK, Lee YT, Hong YK, Jang WK. Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia. Yonsei Med J [Internet]. 2006;47(5):706–14. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2687757&tool=pmcentrez&rendertype=abstract
dc.sourceChuang YC, Chiang PH, Huang CC, Yoshimura N, Chancellor MB. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology. 2005/10/19 ed. 2005;66(4):775–9.
dc.sourceMarberger M, Chartier-Kastler E, Egerdie B, Lee K-S, Grosse J, Bugarin D, et al. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol [Internet]. 2013;63(3):496–503. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23098762
dc.sourceNikoobakht M, Daneshpajooh A, Ahmadi H, Namdari F, Rezaeidanesh M, Amini S, et al. Intraprostatic botulinum toxin type A injection for the treatment of benign prostatic hyperplasia: Initial experience with Dysport. Scand J Urol Nephrol. 2010/03/06 ed. 2010;44(3):151–7.
dc.sourceMarchal C, Perez JE, Herrera B, Machuca FJ, Redondo M. The use of botulinum toxin in benign prostatic hyperplasia. Neurourol Urodyn. 2011/09/10 ed. 2012;31(1):86–92.
dc.sourceArnouk R, Suzuki Bellucci CH, Benatuil Stull R, de Bessa J, Malave CA, Mendes Gomes C. Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: randomized study comparing two doses. ScientificWorldJournal [Internet]. 2012;2012:463574. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3446647&tool=pmcentrez&rendertype=abstract
dc.sourceBrisinda G, Cadeddu F, Vanella S, Mazzeo P, Marniga G, Maria G. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology. 2008/11/11 ed. 2009;73(1):90–4.
dc.sourceSilva J, Silva C, Saraiva L, Silva A, Pinto R, Dinis P, et al. Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur Urol. 2007/09/11 ed. 2008;53(1):153–9.
dc.sourceOeconomou A, Madersbacher H, Kiss G, Berger TJ, Melekos M, Rehder P. Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature. Eur Urol. 2008/06/24 ed. 2008;54(4):765–75.
dc.sourceSilva J, Pinto R, Carvalho T, Botelho F, Silva P, Silva C, et al. Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function. BJU Int. 2010/11/26 ed. 2011;107(12):1950–4.
dc.sourceJadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996/02/01 ed. 1996;17(1):1–12.
dc.sourceinstname:Universidad del Rosario
dc.sourcereponame:Repositorio Institucional EdocUR
dc.subjectHiperplasia prostatica
dc.subjectsíntomas del tracto urinario bajo
dc.subjecttoxina botulínica
dc.subjectscore internacional de síntomas prostáticos
dc.titleToxina botulínica en manejo de síntomas del tracto urinario bajo en pacientes con hiperplasia prostática benigna - revisión sistemática de la literatura
dc.typebachelorThesis


Este ítem pertenece a la siguiente institución